Company Comparison
Oryzon Genomics vs 23andMe
Side-by-side comparison of two portfolio companies — sector, funding stage, investors, valuation, and more.
| Metric | Oryzon Genomics | 23andMe |
|---|---|---|
| Sector | Biotech | Biotech |
| Headquarters | Barcelona, Spain | South San Francisco, California |
| Founded | 2000 | 2006 |
| Status | Active | Active |
| Last Funding Stage | IPO | — |
| Total Funding | $50M | — |
| Valuation | — | — |
What They Build
Oryzon Genomics
Spanish biopharmaceutical company developing epigenetic therapies for cancer and CNS diseases using histone deacetylase and lysine demethylase inhibitors.
23andMe
23andMe Holding Co. is an American personal genomics and biotechnology company based in South San Francisco, California.
Key Investors
Oryzon Genomics
Sector Overlap
Both Oryzon Genomics and 23andMe operate in Biotech.
Browse all Biotech companies →Websites
The operating system for private capital.
Archstone runs the back office for venture, PE, real estate, and credit funds — LP reporting, capital calls, portfolio tracking, and fund accounting, in one platform. Now in alpha.
Now in alpha with select funds. 14-day trial available.